6550-- Ventena Contract Request
Closed Special Notice Posted
This opportunity was awarded. See the award notice from .
- Solicitation number
- 36C25726Q0105
- Agency
-
Veterans Integrated Service Network 17
Veterans Health Administration, Department of Veterans Affairs
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325413 In-Vitro Diagnostic Substance Manufacturing
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The Department of Veterans Affairs Veterans Health Administration, Veterans Integrated Service Network 17, issued a Special Notice on February 3, 2026, announcing its intent to award a sole source, firm-fixed-price contract to Roche Diagnostics Corporation for reagents and consumable supplies. The procurement encompasses 40 line items of specialized diagnostic materials, including detection reagents, staining solutions, antibodies, control kits, and ancillary supplies designed for use with the Ventana BenchMark Ultra automated slide staining system. The VA has determined that these reagents and supplies are exclusively compatible with the Ventana system and cannot be substituted with alternative products. Roche Diagnostics has provided documentation confirming that all Ventana detection reagents, ancillaries, antibodies, and probes are developed and validated exclusively for the fully automated Ventana Benchmark IHC/ISH slide staining system. The sole source justification is made under 41 U.S.C. 3304(a)(1), as implemented by FAR 6.302-1, based on the determination that only one responsible source can satisfy the agency's requirements.
The contract will be structured as a standing order on an indefinite-delivery/indefinite-quantity basis with a five-year ordering period, with supplies to be ordered on an as-needed basis throughout performance. All responsible sources are invited to submit capability statements, proposals, or quotations within five days of publication, with a deadline of February 9, 2026, at 10:00 a.m. Central Time, to allow the government to evaluate whether comparable alternative sources are available and more advantageous. If no affirmative written response is received by the deadline, the contract will be awarded to Roche Diagnostics Corporation. There are no set-aside restrictions on this procurement, meaning any eligible contractor meeting the requirements may respond. The estimated annual quantities for individual line items range from 2 to 80 units, reflecting the VA's ongoing operational needs for diagnostic supplies supporting its healthcare network operations.
Notice text
Special Notice Notice of Intent to Award a Sole Source Procurement
The Department of Veterans Affairs, Veterans Health Administration, Network Contracting Office 17, intends to award a firm-fixed priced contract to Roche Diagnostics Corporation for procurement of the following reagents and consumable supplies:
Estimated Annual Quantities
Item Description
Item Number
Quantity
1
Reagent, DAB Detection
760-500
25
2
Reagent, Stainer, Amplification
760-080
20
3
Reagent, Stainer, Reaction Buffer
950-300
40
4
Reagent, Hematoxylin
760-2021
26
5
Reagent, Bluing Agent
760-2037
26
6
Staining Solution, Protease
760-2018
7
7
10x EZ Stainer, Prep Solution, 2L
950-102
15
8
Benchmark Ultra LCS
650-210
80
9
Solution, Ultra, Cell CC1
950-224
14
10
Control, Negative Monoclonal
760-2014
6
11
Elastin Van Gieson Kit 50 Test
Cat. 09592229001
6
12
Staining Kit, Complex Stains, Reticulum II
860-024
4
13
Staining Kit, Complex Stains, Special
860-028
4
14
DEPAR Solution, BMK Special Stains
860-036
6
15
Liquid Coverslip, BMK Special Stains
860-034
10
16
Benchmark Special Stains Wash II
Catalog 08309817001
8
17
Benchmark Special Stains I Cleaning Kit
860-049
7
18
Ventana H. Pylori (SP48) PAB
790-1014
24
19
CONFIRM ANTI-THRYOID TRANSCRIPTION FACT
790-4398
8
20
Ribbon, Ebar Printer
1632900
3
21
Kit Pack Ebar
1418702
5
22
Confirm Cytokeratin7 Rabbitmono
790-4462
8
23
Antibody KI 67 (30-9) Rabbit Monoclonal
790-4286
8
24
S IHC ANTIBODY ROUTINE: CONFIRM ANTI-S100 (POLYCLONAL) PAB
760-2523
6
25
CONFIRM CYTOKERATIN 20 RABBIT MONO
790-4554
10
26
CONFIRM CYTOKERATIN 20 RABBIT MONO
790-4431
6
27
ANTI-CHROMOGRANIN A (LK2H10) PAB
760-2519
4
28
CONFIRM CYTOKERATIN 20 RABBIT MONO
790-7061
4
29
CD-138 (B-A38) PAB, CELL MARQUE
790-4248
4
30
CONFIRM ANTI-CD34 (QBEND/10) PRIMARY ANTIBODY
790-2927
4
31
CONFIRM ANTI-CD3 (2GV6) RABBIT MONOCLONAL
790-4341
4
32
CONFIRM ANTI-CD5 (SP19) RABBIT MONO
790-4451
4
33
CONFIRM ANTI-CD20 (L26) PAB
760-2531
4
34
CD68 (SP251V18) RABBIT MONOCLONAL AB
790-7248
4
35
VENTANA ANTI-CD10 (SP67)
790-4506
4
36
CONFIRM ANTI-SYNAPTOPHYSIN (SP11) RABBIT
790-4407
4
37
CYTOKERATIN (CAM 5.2) PAB
790-4555
4
38
IHC ANCILLARY, HEMATOXYLIN II
790-2208
2
39
IHC ANCILLARIES, OPTIVIEW AMPLIFICATION KIT
760-099
2
40
IHC ANCILLARIES: OPTIVIEW DAB DETECTION
KIT (250)
760-700
2
The requested items will be used on the Ventana BenchMark Ultra system. The requesting activity states that the government owns and operates a Ventana BenchMark Ultra System and that the requested reagents and consumable supplies are the only supplies compatible with the instrument. A sole source letter from Roche states that all Ventana detection reagents, ancillaries, antibodies and probes are developed and validated for exclusive use on the fully automated Ventana Benchmark IHC/ISH slide staining system and cannot be substituted. The proposed order will be considered a standing order; where, the supplies will be ordered throughout the period of performance, on an as-needed basis. Network Contracting Office 17 will request the acquisition of these supplies from Roche on an IDIQ contract with a five-year ordering period.
This notice is not to be considered a request for quotations or proposals. A contract will not be awarded based on an offer received in response to this notice; however, all responsible sources may submit a capability statement, proposal or quotation, which shall be considered by the agency. Proposals or offers received will be used to determine if a comparable source is available and more advantageous to the government. If no affirmative written response is received within 5 days from the publication of this notice, a contract/order will be issued to Roche Diagnostics Corporation without any further notice.
The proposed contract actions are for supplies, which the government intends to negotiate with only one source. The anticipated statutory authorities permitting other than full and open competition for the requirement is 41 U.S.C. 3304(a)(1), as implemented by FAR 6.302-1, Only one responsible source and no other supplies or services will satisfy agency requirements.
The proposed sole source procurement will be made by an open market pricing agreement with Roche Diagnostics Corporation.
Files
| File | Type | Posted |
|---|---|---|
| 36C25726Q0105.docx | DOCX document |
Notice history
| Notice | Type | Posted |
|---|---|---|
| 6550--NTX Ventana Reagents | Award Notice | |
| This notice | Special Notice |
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| 6550--Notice of Intent to Sole-Source T-SPOT. TB® Reagents and Kits | Veterans Integrated Service Network 2 | No set-aside | |
| 6550--Abbott Architect i1000 Reagents | Veterans Integrated Service Network 22 | No set-aside | |
| Q301--New - CareDx Base + 4 | Veterans Integrated Service Network 17 | No set-aside | |
| 7A21--Siemens UniPOC Licenses and Service | VA Technology Acquisition Center | No set-aside | |
| 6506--Notice of Intent to Sole Source - Lab Supplies (Blood) Altoona VA Medical Center, Altoona, PA | Veterans Integrated Service Network 4 | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity